Loading
Analysing a large chemoradiation trial showed that HPV-positive oropharyngeal cancers have a far better prognosis than HPV-negative ones, with three-year survival of 82 versus 57 percent, and that smoking history further modifies risk.
Retrospective analysis of 323 patients with stage III to IV oropharyngeal cancer treated with cisplatin chemoradiation in RTOG 0129, stratified by tumour HPV status determined by in situ hybridisation and p16 immunohistochemistry.
HPV-positive tumours (63.8 percent) had three-year overall survival of 82.4 versus 57.1 percent (hazard ratio for death 0.42 after adjustment), and a recursive partitioning model combining HPV status, pack-years of smoking, T stage and N stage defined low, intermediate and high-risk groups.
HPV-positive oropharyngeal cancer is now staged and studied separately, and this risk model underlies de-escalation trials and the eighth-edition staging system.
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue).
Shares HPV-positive oropharyngeal cancer, HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer).
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue).
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), New England Journal of Medicine.
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue).
Shares HPV-positive oropharyngeal cancer, Oropharyngeal cancer (tonsil and base of tongue).
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), New England Journal of Medicine.
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), New England Journal of Medicine.